Contribution: Industrial Research Assistance Program – Contributions to Firms
ImmunoPrecise Antibodies (Canada) Ltd
$150,050.00
Development of a unique next generation end-to-end antibody discovery platform
FY 2021-22 · 2021-07-01
Summary
This project will support the development a one-of-a-kind antibody discovery platform, through the integration of a new single B cell technology using innovative memory, plasma and repertoire B cell workflows, with Next Generation Sequencing (NGS), machine learning and recombinant protein production.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Victoria|Victoria, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
894660174
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-07-01 | 2021-22 | $246,910.00 |
| 1 | 2021-07-01 | 2021-22 | $187,994.00 |
| 2 | 2021-07-01 | 2021-22 | $150,050.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 212 days. The total amended value is -37,944 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 212 jours. La valeur totale des modifications est de - 37 944 dollars.
Agreement End Date
2023-08-31
Agreement Number
981804
Agreement Start Date
2021-07-01
Agreement Title
Development of a unique next generation end-to-end antibody discovery platform
Agreement Title (French)
Développement d'une plateforme unique de découverte d'anticorps de bout en bout de nouvelle génération
Agreement Type
Contribution
Agreement Value
$150,050.00
Amendment Date
2023-02-06
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will support the development a one-of-a-kind antibody discovery platform, through the integration of a new single B cell technology using innovative memory, plasma and repertoire B cell workflows, with Next Generation Sequencing (NGS), machine learning and recombinant protein production.
Description (French)
Ce projet soutiendra le développement d'une plateforme de découverte d'anticorps unique en son genre, par l'intégration d'une nouvelle technologie de cellules B unique utilisant des flux de travail innovants pour les cellules B de mémoire, de plasma et de répertoire, avec le séquençage de nouvelle génération (SNG), l'apprentissage machine et la production de protéines recombinantes.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Esquimalt--Saanich--Sooke
Federal Riding (French)
Esquimalt--Saanich--Sooke
Federal Riding Number
59026
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
894660174
Recipient City
Victoria|Victoria
Recipient Country
CA
Recipient Legal Name
ImmunoPrecise Antibodies (Canada) Ltd
Recipient Operating Name
ImmunoPrecise Antibodies
Recipient Postal Code
V8Z 7X8
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2021-2022-Q3-981804
